The objective of this study was to investigate the risk of acute internal jugular, subclavian, and axillary deep venous thrombosis (upper torso DVT [UTDVT]) and pulmonary embolism (PE) and the ...

Oppenheimer initiated coverage of Penumbra (PEN) with an Outperform rating and $275 price target Penumbra is a leader in the mechanical ...

Oppenheimer initiated coverage of Inari Medical (NARI) with an Outperform rating and $75 price target Inari is a leader in the thrombectomy ...

Chicago-based Flow Medical is developing a new thrombolysis system for treating acute pulmonary embolism (PE).

Oppenheimer predicts growth for Penumbra Inc in MT market. Analyst initiates coverage with Outperform rating and $275 target ...

A blood clot is a lump of blood that can form in various body parts, including the legs, arms, lungs or heart. These clots ...

The National Consumer Disputes Redressal Commission (NCDRC) recently exonerated a Thiruvananthapuram-based hospital and its ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

Fintel reports that on December 17, 2024, Oppenheimer initiated coverage of Inari Medical (NasdaqGS:NARI) with a Outperform ...

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

Oppenheimer initiated coverage on shares of Inari Medical (NASDAQ:NARI – Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage issued an outperform rating and a $75.00 price ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $60.67, a high estimate of $75.00, ...